Study of the Cancer Treatment Drugs Availability Effect on Overall Survival
The issue of accessibility of new drugs is always an acute one, as for patients and for doctors, as well as the healthcare system managers. The appropriateness of speeding up market approval for new drugs was assessed using the example of the markets of the Russian Federation and the USA. The nomenclature of available antitumor drugs was compared and comparison of data on mortality caused by malignant neoplasms was performed. The results showed that with the availability of new drugs for the treatment of cancer, mortality did not show the expected decline, but increases in the United States by an average of 2.51% per year for the period from 2013 to 2017. Moreover, in the absence of 74% of new antitumor drugs on the market of the Russian Federation, mortality decreases by an average of 0.74% per year over the same period. The results retain their orientation when individually considering different age groups and localization of neoplasms, which indicates the general nature of the described phenomenon.